A Study To Find The Best Doses Of SU011248 And Gemcitabine When Given Together To Patients With Advanced Solid Tumors
This study assesses the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with gemcitabine in patients with advanced solid tumors
Solid Tumors
DRUG: SU011248; Gemcitabine
To determine the maximally tolerated dose of SU011248 (dosed on Schedule 4/2 or 2/1) when given in combination with gemcitabine, From screening until at least 28 days beyond discontinuation of study treatment
To evaluate the pharmacokinetics of SU011248 and gemcitabine when these drugs are co-administered, From screening until at least 28 days beyond discontinuation of study treatment|To preliminarily assess the antitumor activity of SU011248 and gemcitabine in patients with measurable disease, From screening until at least 28 days beyond discontinuation of study treatment
This study assesses the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with gemcitabine in patients with advanced solid tumors